You are here

FDA Slams Duodenoscope Makers Over Failure to Complete Studies

In one case, a required postmarket surveillance study hasn’t even started

The FDA has  issued warning letters to all three duodenoscope manufacturers for failing to comply with requirements of federal law under which they were ordered to conduct postmarket surveillance studies to assess the effectiveness of reprocessing the devices.

As part of an ongoing effort to prevent patient infections associated with the transmission of bacteria from contaminated duodenoscopes, the FDA in 2015 ordered U.S. duodenoscope manufacturers Olympus, Fujifilm, and Pentax to conduct a postmarket surveillance study to determine whether health care facilities were able to properly clean and disinfect the devices. Specifically, as part of their approved study plans, all three manufacturers are required to conduct a study to sample and culture reprocessed duodenoscopes that are in clinical use to learn more about issues that contribute to contamination, as well as a human factors study to assess how well trained hospital staff are following the reprocessing instructions.

To date, Olympus has failed to start data collection, and Pentax and Fujifilm have failed to provide sufficient data, as required for their respective studies to sample and culture reprocessed duodenoscopes that are in clinical use, the FDA said. Olympus and Pentax also have not complied with requirements for their respective human factors studies to assess how well hospital staff are following reprocessing instructions; Fujifilm has been meeting its requirements for its human factors study.

“The FDA has taken important steps to improve the reprocessing of duodenoscopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly implemented in real world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, MD, director of the FDA’s Center for Devices and Radiological Health. “We expect these device manufacturers to meet their study obligations to ensure patient safety.”

Duodenoscopes are flexible, lighted tubes that are threaded through the mouth, throat and stomach into the top of the small intestine (duodenum) and are used during endoscopic retrograde cholangiopancreatography, a potentially life-saving procedure to diagnose and treat problems in the pancreas and bile ducts. In 2013, the FDA learned about a potential association between multidrug resistant bacteria and duodenoscopes. Upon further investigation, it became clear that these cases of infection were occurring despite confirmation that device users were following proper manufacturer cleaning and disinfection or sterilization instructions.

Since then, the FDA has worked with all three duodenoscope manufacturers that market duodenoscopes in the U.S. to review validated processing instructions and to take corrective actions to remove and replace models from the market with faulty designs that made them difficult to clean and reprocess. On February 26, 2018, the FDA, Centers for Disease Control and Prevention, and the American Society for Microbiology,  together with other endoscope culturing experts, released voluntary standardized protocols for duodenoscope surveillance sampling and culturing. For health care facilities that choose to implement duodenoscope surveillance sampling and culturing, these protocols can be used to help monitor the quality of a facility’s endoscope reprocessing procedures. Adequate monitoring may reduce the risk of infection.

FDA expects that Olympus, Fujifilm, and Pentax will submit a plan by March 24, 2018, that outlines how study milestones will be achieved. For the sampling and culturing study, the FDA expects 50% of samples collected in the study to be processed by August 31, 2018, and 100% by the end of 2018. For Olympus’s and Pentax’s human factors studies, the agency expects 50% of testing to be completed by May 31, 2018, and 100% by June 30, 2018. If the companies fail to adequately respond to the warning letter, the FDA may take additional action such as seizure, injunction, and civil money penalties.

The FDA continues to work with manufacturers and other stakeholders to improve the safety of duodenoscopes and other reusable medical devices to help protect patients from bacterial infections associated with these medical devices.

Source: FDA; March 9, 2018.

More Headlines

More drugs or more costly drugs are being prescribed, industry trade group says
Risk approaches 13% for women who fall ill early in pregnancy
Alexion announces positive top-line results for ALXN1210 in PNH
Increased risk of high-frequency hearing loss pegged at 60%
Janssen drug targets metastatic urothelial cancer, marked by poor outcomes
Researchers say this real-world study in Canada should also apply to the U.S.
The results from a seven-year study were “entirely unexpected”
Generic competition pushed back to at least mid-2018
Report identifies critical need to minimize financial toxicity and increase access